Apply now: feature your voice in our cell & gene therapy series
Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community?
We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice!
In a study by Fang (2025), researchers used a method called Mendelian randomization to explore whether there's a genetic link between the number of white blood cells in the blood and the likelihood of developing IgA nephropathy. They found that certain white blood cells, specifically transitional B cells, might play a role in the development of this condition. This was determined by looking at genetic variations that are known to affect the levels of these cells and seeing if those same variations were more common in people with IgA nephropathy.
The findings suggest that having a higher count of these specific white blood cells could increase the risk of developing IgA nephropathy. This research could lead to better understanding of the disease and potentially to new ways to predict or prevent it. However, it's important to remember that this study looks at genetic predisposition and doesn't prove direct causation. Further research is needed to confirm these results and to explore the mechanisms involved.
